|
Domain 1: scope and purpose
|
|
1. Overall objectives specific
|
21
|
20
|
21
|
17
|
18
|
18
|
19
|
17
|
15
|
16
|
13
|
14
|
209
|
83
|
|
2. Health questions specific
|
18
|
20
|
21
|
19
|
21
|
9
|
18
|
16
|
14
|
15
|
13
|
9
|
193
|
77
|
|
3. Population is specific
|
18
|
21
|
20
|
16
|
20
|
8
|
20
|
17
|
16
|
20
|
17
|
12
|
205
|
81
|
|
Domain 2: stakeholder involvement
|
|
4. Guideline development group
|
19
|
18
|
20
|
15
|
21
|
15
|
18
|
19
|
20
|
7
|
6
|
10
|
188
|
75
|
|
5. Views and preferences of target population
|
5
|
21
|
18
|
11
|
21
|
6
|
7
|
14
|
2
|
4
|
3
|
3
|
115
|
46
|
|
6. Target users clearly defined
|
20
|
16
|
20
|
21
|
21
|
16
|
18
|
19
|
18
|
17
|
12
|
4
|
202
|
80
|
|
Domain 3: rigor of development
|
|
7. Systematic methods
|
15
|
17
|
21
|
21
|
21
|
19
|
10
|
13
|
12
|
6
|
16
|
4
|
175
|
69
|
|
8. Criteria for evidence selection
|
14
|
19
|
21
|
21
|
21
|
17
|
5
|
15
|
19
|
7
|
16
|
4
|
179
|
71
|
|
9. Strengths and limitations of evidence
|
13
|
19
|
20
|
18
|
18
|
6
|
5
|
20
|
19
|
10
|
9
|
4
|
161
|
64
|
|
10. Methods for formulating recommendations
|
19
|
17
|
21
|
18
|
19
|
8
|
10
|
21
|
17
|
5
|
8
|
11
|
174
|
69
|
|
11. Health benefits, side-effects, risks were considered in formulating recommendations
|
20
|
19
|
19
|
17
|
19
|
19
|
21
|
21
|
9
|
18
|
12
|
20
|
214
|
85
|
|
12. Explicit link between recommendations and evidence
|
19
|
17
|
21
|
20
|
21
|
12
|
10
|
19
|
17
|
11
|
12
|
12
|
191
|
76
|
|
13. Externally reviewed prior to publication
|
15
|
18
|
21
|
16
|
21
|
6
|
16
|
18
|
15
|
7
|
10
|
9
|
172
|
68
|
|
14. A procedure for updating guideline
|
13
|
20
|
15
|
20
|
19
|
5
|
4
|
18
|
3
|
3
|
14
|
3
|
137
|
54
|
|
Domain 4: clarity of presentation
|
|
15. Recommendations specific; unambiguous
|
20
|
19
|
21
|
20
|
20
|
18
|
17
|
20
|
17
|
15
|
13
|
18
|
218
|
87
|
|
16. Different options for management
|
18
|
19
|
14
|
21
|
21
|
20
|
13
|
18
|
18
|
15
|
15
|
16
|
208
|
83
|
|
17. Key recommendations easily identifiable
|
20
|
19
|
21
|
20
|
21
|
18
|
16
|
20
|
19
|
14
|
12
|
14
|
214
|
85
|
|
Domain 5: applicability
|
|
18. Barriers and facilitators to application
|
15
|
16
|
19
|
20
|
17
|
11
|
6
|
8
|
11
|
4
|
4
|
5
|
136
|
54
|
|
19. Advice/Tools to put recommendations to practice
|
14
|
20
|
21
|
20
|
18
|
8
|
13
|
10
|
9
|
7
|
8
|
6
|
154
|
61
|
|
20. Potential resource limitations have been considered
|
9
|
13
|
12
|
18
|
15
|
11
|
7
|
12
|
4
|
3
|
3
|
3
|
110
|
44
|
|
21. Monitoring and audit criteria
|
15
|
20
|
14
|
20
|
19
|
20
|
9
|
13
|
3
|
8
|
8
|
3
|
152
|
60
|
|
Domain 6: editorial independence
|
|
22. Views of funding body vs guideline content
|
20
|
21
|
21
|
15
|
10
|
20
|
14
|
21
|
12
|
21
|
3
|
17
|
195
|
77
|
|
23. Competing interests of guideline development group members have been recorded and addressed
|
21
|
21
|
21
|
15
|
20
|
21
|
8
|
21
|
3
|
21
|
3
|
20
|
195
|
77
|
